Last month, the University of Louisville (UofL) reported on a breakthrough use of cell therapy, that is stem cells derived from a patient’s own bone marrow and heart led to improved quality of life as well as fewer serious cardiac events for the patient. At UofL, the study was led by a cell therapy and cardiovascualr research pioneer, Roberto Bolli, director of the UofL Institute of Molecular Cardiology; the principal investigator suggested that based on the results of the CONCERT-HF study, a bigger Phase 3 clinical trial to investigate the efficacy of this cell therapy addressing heart failure was in order. UofL reported that it enrolled 25% of the 125 trial-participating patients, making it the most productive trial site in this important study conducted by the Cardiovascular Cell Therapy Research Network (CCTRN).
The Condition: Ischemic Cardiomyopathy
This is a type of cardiomyopathy triggered by a narrowing of the coronary arteries, which supply blood to the heart. Often those patients afflicted with ischemic cardiomyopathy face a history of acute myocardial infarction (heart attack) but it can also happen in patients with coronary artery disease, less a past history of ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).